Nuvalent (NUVL) Competitors $77.23 -1.39 (-1.77%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$77.21 -0.02 (-0.03%) As of 08/6/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVL vs. INSM, SMMT, TEVA, GMAB, RDY, QGEN, MRNA, ASND, VTRS, and BBIOShould you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Nuvalent vs. Its Competitors Insmed Summit Therapeutics Teva Pharmaceutical Industries Genmab A/S Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris BridgeBio Pharma Nuvalent (NASDAQ:NUVL) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Which has stronger earnings and valuation, NUVL or INSM? Nuvalent has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.39-17.59Insmed$363.71M58.03-$913.77M-$5.95-18.70 Do insiders & institutionals hold more shares of NUVL or INSM? 97.3% of Nuvalent shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by company insiders. Comparatively, 3.0% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor NUVL or INSM? In the previous week, Insmed had 1 more articles in the media than Nuvalent. MarketBeat recorded 8 mentions for Insmed and 7 mentions for Nuvalent. Nuvalent's average media sentiment score of 1.19 beat Insmed's score of 0.77 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate NUVL or INSM? Nuvalent currently has a consensus target price of $119.60, indicating a potential upside of 54.86%. Insmed has a consensus target price of $109.20, indicating a potential downside of 1.85%. Given Nuvalent's stronger consensus rating and higher possible upside, equities analysts clearly believe Nuvalent is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Insmed 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, NUVL or INSM? Nuvalent has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Insmed has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Is NUVL or INSM more profitable? Nuvalent has a net margin of 0.00% compared to Insmed's net margin of -265.93%. Nuvalent's return on equity of -31.35% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -31.35% -29.27% Insmed -265.93%-446.98%-52.70% SummaryNuvalent beats Insmed on 13 of the 16 factors compared between the two stocks. Get Nuvalent News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVL vs. The Competition Export to ExcelMetricNuvalentMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.65B$3.01B$5.56B$9.47BDividend YieldN/A2.41%4.31%4.17%P/E Ratio-17.5916.5729.3723.99Price / SalesN/A313.98444.7496.71Price / CashN/A42.1735.8458.51Price / Book5.157.818.085.58Net Income-$260.76M-$54.52M$3.26B$265.35M7 Day Performance-1.43%0.41%0.44%-0.07%1 Month Performance-0.90%9.93%4.82%1.76%1 Year Performance14.52%15.18%30.27%25.39% Nuvalent Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVLNuvalent3.3643 of 5 stars$77.23-1.8%$119.60+54.9%+8.5%$5.65BN/A-17.5940Positive NewsUpcoming EarningsINSMInsmed3.7803 of 5 stars$111.24+2.3%$109.20-1.8%+53.1%$20.62B$363.71M-18.701,271SMMTSummit Therapeutics2.0952 of 5 stars$29.32+8.3%$34.67+18.2%+199.0%$20.10B$700K-86.23110Positive NewsTEVATeva Pharmaceutical Industries3.381 of 5 stars$15.70+2.1%$24.71+57.4%-5.1%$17.64B$16.54B-98.1336,830Positive NewsInsider TradeGMABGenmab A/S3.6734 of 5 stars$21.98+0.9%$37.80+72.0%-18.7%$13.97B$3.12B12.492,682Positive NewsUpcoming EarningsShort Interest ↑RDYDr. Reddy's Laboratories2.6041 of 5 stars$13.80-1.0%$16.95+22.9%-18.3%$11.64B$334.26B20.9027,811QGENQiagen3.5373 of 5 stars$50.27+0.7%$49.40-1.7%+9.2%$11.10B$1.98B126.045,765Trending NewsEarnings ReportMRNAModerna4.265 of 5 stars$27.64+0.1%$45.61+65.0%-67.5%$10.68B$3.24B-3.675,800Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionASNDAscendis Pharma A/S2.6256 of 5 stars$184.15+5.5%$223.67+21.5%+45.5%$10.67B$393.54M-29.321,017VTRSViatris2.2557 of 5 stars$8.94+1.5%$10.40+16.3%-22.9%$10.34B$14.74B-2.8232,000Dividend AnnouncementShort Interest ↑BBIOBridgeBio Pharma4.7207 of 5 stars$47.75+0.8%$61.18+28.1%+80.2%$8.99B$221.90M-13.53400Earnings ReportAnalyst ForecastOptions VolumeGap Down Related Companies and Tools Related Companies INSM Competitors SMMT Competitors TEVA Competitors GMAB Competitors RDY Competitors QGEN Competitors MRNA Competitors ASND Competitors VTRS Competitors BBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NUVL) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NUVL Stock Alerts